Adenosine Receptors Influence Ischemia-Reperfusion Injury
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Ischemic preconditioning is defined as the development of tolerance to ischemia-reperfusion injury by a previous short bout of ischemia resulting in a marked reduction in infarct size. This mechanism can be mimicked by several pharmacological substances such as acetylcholine and adenosine.
To detect ischemia-reperfusion injury in humans in vivo Kharbanda et al. developed a method in which endothelial dysfunction represents the effects of ischemic preconditioning. This method, however, uses acetylcholine to measure endothelial function before and after forearm ischemia. We, the investigators at Radboud University, hypothesize that the use of acetylcholine in this model reduces ischemia-reperfusion injury. Therefore, we will compare this protocol with a protocol in which endothelial function is only measured after ischemia. We expect an increase in ischemia-reperfusion injury when endothelial function is only measured after the forearm ischemia.
After determining the optimal method to measure ischemia-reperfusion injury of the vascular endothelium we will determine the effect of acute and chronic caffeine, an adenosine receptor antagonist, on ischemic preconditioning. With this study we expect to find that adenosine mimics ischemic preconditioning of the vascular endothelium. Moreover, we expect to find that acute caffeine intake reduces ischemia-reperfusion injury whereas chronic caffeine intake does not. This study will increase our knowledge about the mechanism of ischemic preconditioning and may also provide leads to exploit this endogenous protective mechanism in a clinical setting.
| Condition | Intervention |
|---|---|
|
Ischemia-Reperfusion Injury |
Drug: acetylcholine Procedure: twenty minutes of forearm ischemia Procedure: three 5-minute periods of forearm ischemia Drug: adenosine Drug: caffeine |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double-Blind |
| Official Title: | Adenosine Receptor Involvement in Acute Ischemic Preconditioning of the Vascular Endothelium |
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy volunteers
Contacts and Locations| Netherlands | |
| Radboud University Nijmegen Medical Centre/Department of Pharmacology and Toxicology | |
| Nijmegen, Gelderland, Netherlands, 6500 HB | |
| Principal Investigator: | Gerard Rongen, MD, PhD | Radboud University Nijmegen Medical Centre/Department of Pharmacology and Toxicology |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00184847 History of Changes |
| Other Study ID Numbers: | ACAD |
| Study First Received: | September 12, 2005 |
| Last Updated: | March 27, 2008 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by Radboud University:
|
acetylcholine adenosine caffeine ischemic preconditioning |
Additional relevant MeSH terms:
|
Ischemia Reperfusion Injury Pathologic Processes Vascular Diseases Cardiovascular Diseases Postoperative Complications Acetylcholine Adenosine Caffeine Vasodilator Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Cholinergic Agonists Cholinergic Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Anti-Arrhythmia Agents Central Nervous System Stimulants Phosphodiesterase Inhibitors Enzyme Inhibitors Purinergic P1 Receptor Antagonists Purinergic Antagonists Purinergic Agents |
ClinicalTrials.gov processed this record on June 18, 2013